New trial
Phase 1 HaploCord Transplant: Unmodified cord blood graft for hematologic malignancies.
- Trial ID
- NCT06904482 on ClinicalTrials.gov
- Cancer type
- Hematological Cancer
- Stage of research
- Exploratory
- Published in
- New in Oncology - July 3, 2025
This trial at Case Comprehensive Cancer Center in Cleveland investigates whether combining haplo‐identical donor and cord blood transplants can yield durable disease‐free survival in patients with AML or ALL. Patients receive this investigational transplant regimen to evaluate safety and efficacy.
More in other blood cancers and transplant
-
Trial result · Aug 13, 2026 · NCT04904588
Standard-dose PTCy enables mismatched-donor HCT but carries substantial early infection burden -
Trial result · Aug 6, 2026 · NCT05388123
Low-dose vemurafenib (BRAF V600E inhibitor) + rituximab drives 73% CR with zero grade 3-4 AEs in HCL -
Trial result · Aug 6, 2026 · NCT02113982
Tagraxofusp (CD123-directed cytotoxin) in BPDCN delivers 71%–90% ORR across trials—HSCT bridge drives survival -
New trial · Jun 25, 2026 · NCT07634536
Phase 2 automated VMAT-based TMLI conditioning refines marrow / lymphoid-targeted irradiation for allo-HCT. -
New trial · Jun 25, 2026 · NCT07572006
Phase 1 JNJ-95804306 (no disclosed MOA/target) in relapsed/refractory AML/MDS and CLL/SLL